Registry for Long COVID in Children and Adults
Munich Long COVID Registry for Children, Adolescents, and Adults (MLC-R)
This study is collecting information from children and adults who have Long COVID to better understand its effects and help improve care for those affected.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Technical University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT05638724 on ClinicalTrials.gov |
What this trial studies
The Munich Long COVID Registry aims to gather extensive data on the epidemiology, phenotypes, and disease trajectories of Long COVID across all ages in Germany. This observational study will collect information on individuals who have experienced post-COVID conditions, including symptoms that persist beyond four weeks after acute COVID-19. The registry will serve as a valuable resource for future clinical trials and research into the long-term effects of SARS-CoV-2. By understanding the prevalence and impact of Long COVID, the study seeks to improve healthcare responses and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals of any age who have experienced confirmed SARS-CoV-2 infection or vaccination and are suffering from post-COVID symptoms.
Not a fit: Patients whose symptoms can be attributed to other underlying diseases or who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of Long COVID, leading to better treatment options and improved quality of life for affected patients.
How similar studies have performed: Other studies have shown promise in understanding Long COVID, but this registry approach is relatively novel in its comprehensive data collection across different age groups.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: I. Written informed consent of the patient or legal guardian. II. Confirmed SARS-CoV-2 vaccination and/or confirmed or probable SARS-CoV-2 infection: Positive SARS-CoV-2 polymerase chain reaction (PCR) or rapid antigen test (AST), documented probable COVID-19 (e.g., typical CT scan), probable COVID-19 with a history of high-risk contact, anti-SARS-CoV-2-N antibodies (and/or in non-vaccinated people -S-IgG antibodies) following probable COVID-19. III. Additional ICD-10 codes: U09.9!V: Suspected post-COVID-19 condition, unspecified; U12.9!V: suspected adverse reactions to COVID-19 vaccine use, unspecified (post-COVIDvac condition). Exclusion Criteria: * Any subsequent medical data that question the diagnosis of PCC or post-COVIDvac condition * Clinical picture can be explained by another underlying disease. * Pregnancy
Where this trial is running
Munich, Bavaria
- MRI Chronic Fatigue Center for Young People (MCFC) Children's Hospital, Technical University of Munich & Munich Municipal Hospital — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Uta Behrends, Prof. Dr. med. — MRI Chronic Fatigue Center for Young People (MCFC), Children's Hospital, Technical University of Munich & Munich Municipal Hospital
- Study coordinator: Uta Behrends, Prof. Dr. med.
- Email: uta.behrends@tum.de
- Phone: +4989 3068 2632
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.